

JAMES ALLEN THOMPSON M.D. Ph.D.**CURRENT POSITION**

- 1/2004-** **Ambry Genetics** **Aliso Viejo, CA**
Medical Director
- Clinical Laboratory
 - Responsible for Direction of CLIA certified testing services in the areas of molecular diagnostics.
- 10/2003-** **Pathogenesys LLC** **Irvine, CA**
CEO and Medical Director
- Clinical Laboratory
 - Responsible for Direction of CLIA certified Oncology testing services in the areas of drug resistance testing, flow cytometry, histology, immunohistochemistry, FISH testing, and molecular diagnostics.
 - Pharmaceutical Services
 - Responsible for Direction of GLP Contract Research services.
 - Responsible for Profitability of Contract Research performed for pharmaceutical and biotech companies.
 - Responsible for client contact, protocol and contract preparation and delivery of presentations.
 - Responsible for directing activities of GLP Study Directors.
 - Responsible for evaluation and development of business relationships.
 - Pathologist
 - Responsible for research pathology.
- 10/2005-** **Genoptix Inc.** **Carlsbad, CA**
Senior Hematopathologist
- Clinical Laboratory
 - Responsible for interpretation of testing services in the areas of drug resistance testing, flow cytometry, histology, immunohistochemistry, FISH testing, cytogenetics and molecular diagnostics.

EXPERIENCE and EDUCATION

- 7/2004- 10/2005** **USLABS** **Irvine, CA**
Medical Director
- Clinical Laboratory
 - Responsible for Direction of CLIA certified Oncology testing services in the areas of flow cytometry, histology, immunohistochemistry, FISH testing, cytogenetics, and molecular diagnostics.
 - Pathologist
 - Responsible for interpretation of above technologies applied to patient material..

3/2002- 10/2003

Oncotech, Inc.

Tustin, CA

Vice President and Medical Director

- Clinical Laboratory
 - Responsible for Direction of CLIA certified Oncology testing services in the areas of drug resistance testing, flow cytometry, histology, immunohistochemistry, FISH testing, molecular diagnostics, and Cytogenetics.
- Pharmaceutical Services
 - Responsible for Direction of GLP Contract Research services.
 - Responsible for Profitability of Contract Research performed for pharmaceutical and biotech companies.
 - Responsible for client contact, protocol and contract preparation and delivery of presentations.
 - Responsible for directing activities of GLP Study Directors.
 - Responsible for evaluation and development of business relationships.
- Pathologist
 - Responsible for research pathology.

9/2001-3/2002

Oncotech, Inc.

Tustin, CA

Vice President of Business Development

- Business Development/Sales
 - Responsible for Profitability of contract research performed for pharmaceutical and biotech companies.
 - Responsible for client contact, protocol preparation and delivery of presentations.
 - Responsible for evaluation and development of business relationships.
- Pathologist
 - Responsible for research pathology

11/1998- 8/2001

IMPATH Predictive Oncology

Los Angeles, CA

Medical Director/Vice President of Technology Development

- Medical Director
 - Responsible for direction and assurance of quality of testing performed in GLP-qualified immunohistochemistry, minimal residual disease testing, drug resistance testing and molecular laboratories in Los Angeles.
- Technology Development
 - Responsible for the development and implementation of new test and raw material isolation methodology including flow cytometry, ELISA, sequencing, molecular analyses and cellular activation analyses.
- Business Development/Sales
 - Responsible for sponsor contact and preparation and delivery of presentations.
 - Responsible for evaluation and development of business relationships.
- Management
 - Responsible for the management of laboratory pathologists, managers and technicians.

- Basic Research on lymphocyte activation and anti-cancer therapies in animal models and human clinical trials.

P.I.- UCI96-04 "A Phase II Study to Establish the Clinical Effects of Intratumoral Implants of Alloactivated, Allogeneic Lymphoid Cells in Patients with Recurrent Glioblastoma-Good Samaritan Hospital".

Co-P.I.- "A Phase II Study of Intratumoral Implants of Alloactivated, Allogeneic Lymphoid Cells (CYTOIMPLANTS) in Adult Patients with Progressing or Recurrent Malignant Astrocytomas of the Brain".

Co-P.I. "A Phase I Study of Intratumoral Implants of Alloactivated, Allogeneic Lymphoid Cells (CYTOIMPLANTS) in Adult Patients with Unresectable Pancreatic Cancer".

1995-1996 Pathology, University of California Irvine, CA

Director of Cancer Center Immunotherapy Laboratory

- Medical and Laboratory Director of Laboratory.
 - Responsible for conduct and quality of the Facility. This facility produced a cellular implant used in a multi-institutional Phase 2 clinical trial for the treatment of Glioblastoma Multiformi Brain Cancer patients and in a Phase 1 clinical trial at UCIMC for the treatment of Pancreatic Cancer patients. This includes the development of policies and procedures required for GMP/GLP Federal compliance, design and implementation of in-process and final product identity and potency tests, and development of a Quality System.

1994- 1995 Pathology, University of California Irvine, CA

Fellow, Hematopathology

- 1 year Fellowship in Hematopathology under Dr. Michael Samoszuk and Dr. James Baker (Long Beach Memorial Hospital, Long Beach , CA).
- Medical Student and Resident Teaching.
- Basic Research on lymphocyte activation and anti-cancer therapies in animal models.

1992- 1994 Pathology, Stanford University Stanford, CA

Resident Fellow in Molecular Pathology

- Basic Pathology Research under Dr. Eugene Butcher.
- Basic Research on lymphocyte adhesion molecule cloning and functional analysis in animal models.

1988- 1992 Pathology, Stanford University Stanford, CA

Intern and Resident, Anatomic Pathology

- Anatomic Pathology Training.
- Extracurricular training in Hematopathology under Dr. Howard Sussman and Dr. Joanne Kornbleet.
- Basic Research on Thrombin Receptor Isolation.

1980- 1988 University of California Irvine, CA

Medical and Graduate Student

1. Rodriguez, E., Reynolds, G., Thompson, J., Potent Contact Allergen in Rubber Plant Guayule (*Parthenium argentatum*). *Science* 1981; 211:1444-45.
2. Knauer, DJ., Thompson, J.A., Cunningham, D.D. Protease Nexins: Cell Secreted Proteins That Mediate Binding, Internalization, And Degradation of Regulatory Serine Proteases. *J. Cell. Physiol.* 1983; 117:385-390.
3. Thompson, J.A., Lau, A., Cunningham, D.D. Selective Radiolabeling of Cell Surface Proteins to a High Specific Activity. *Biochemistry* 1987; 26:743-747.
4. Thompson, J.A., McEvoy, LM., and Butcher, E. Molecular Cloning of a Monocyte Adhesion Molecule Involved in Trafficking of Monocytes to Areas of Inflammation. (in preparation).
5. Thompson J.A., Samoszuk, M. Nature and Specificity of IL-4 Mediated Antitumor Immunity Against Lymphoma Cells. *Am J. Pathology* (submitted).
6. Thompson, J.A., Ioli, G. An Easy Method for Cloning Mammalian Cell Colonies. *BioTechniques* 1997; 22 (4): 612-4.
7. Chang, K., Nyugen, P., Kurosaki, T., Thompson, JA., Granger, GA. Phase I Trial of Intratumoral Implants of Allogeneic Peripheral Blood Mononuclear Cells Sensitized against Patient Alloantigens by Mixed Lymphocyte Culture for Patients with Unresectable Pancreatic Carcinoma. *Cancer* 2000; 88(6): 1325-35.
8. Kaur, TB., Shen, T., Gaughan, J., Thompson, J., Houck, KL., Richardson, M., Hernandez, E. Premalignant Lesions in the Contralateral Ovary of Women with Unilateral Ovarian Carcinoma. *Gynecol. Oncol.* 2004; 93(1):69-77.

Review:

1. Thompson, J.A., Cunningham, D.D. Identification of Proteins Sensitive to Proteolysis by Thrombin. *Methods in Enzymology* 1987; 147:157-160.

Abstracts:

1. Thompson, J.A., Knauer, D.J., Cunningham, D.D. Protease Nexin Mediated Cellular Binding of the Regulatory Serine Proteases. *Clinical Research.* 1983; 31(1):36A.
2. Thompson, J.A., Cunningham, D.D. A Comparison Between Plasma Serine Protease Inhibitors and Protease Nexin. *Clinical Research.* 1984; 32(1):35A.
3. Lau, A., Thompson, J.A., Cunningham, D.D. A Novel Method for Specific Radiolabeling of Membrane Proteins. *J. Cell. Biochem., Suppl.* 1986; 10A:E42.
4. Thompson, J.A., Lau, A., Cunningham, D.D. Specific Labeling of Cell Surface Proteolytic Products. *J. Cell. Biochem., Suppl.* 1986; 1CA-E95.
5. Thompson, J.A., Ioli, G. The Effect of Cytokines on Antitumor Immunity Against Lymphoma in Mice. International Conference on Gene Therapy of Cancer (in press).
6. Chang KJ, Nguyen PT, Thompson JA, Kurosaki TT, Casey LR, Leung EC: Phase I Clinical Trial of Allogeneic Mixed Lymphocyte Culture (Cytoimplant) Delivered by Endoscopic Ultrasound (EUS)-Guided Fine Needle Injection (FNI) in Patients with Advanced Pancreatic Carcinoma. *Gastroenterology* 1997; 112(4):A 546.

7. Chang KJ, Nguyen PT, Thompson JA, Kurosaki TT, Casey LR, Leung EC: Phase I Clinical Trial Of Local Immunotherapy (Cytoimplant) Delivered By Endoscopic Ultrasound (EUS) Guided Fine Needle Injection (FNI) In Patients With Advanced Pancreatic Carcinoma. *Gastrointestinal Endoscopy* 1998; 47(4):144, A 480.
8. Cheeks AM., Hargrove JR., Tagle CC., Wallar GM., Astrow SH., Thompson JA., Gammon S. Expression of Multiple Growth Factor Receptors in Breast Cancer. *Breast Cancer Research and Treatment* 1999; 57(1): 132.
9. Manni, A., Astrow, S., Thompson, J., Washington, S., Gammon, S. Expression of Ornithine Decarboxylase (ODC) by Normal and Malignant Mammary Epithelial Cells in Women with Breast Cancer. 2001 May. *Breast Cancer Res Treat.* 67(2):147-56.
10. Kerfoot, CA., Thompson, J., Richardson, M., Pavich, D., Ramsinghani, S., Goddard, A., Eberhard, DA. In Vitro Activity of Tarceva in Primary Lung and Colon Cancer Cells. AACR 2003, Abstract R3796.